Detalhe da pesquisa
1.
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Blood
; 139(24): 3519-3531, 2022 06 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35192684
2.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol
; 22(9): 1250-1264, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34388386
3.
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Breast Cancer Res Treat
; 160(2): 305-312, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27714541
4.
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
J Transl Med
; 14: 12, 2016 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-26762579
5.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(1): 257-264, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38049622
6.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Blood Adv
; 2024 Mar 26.
Artigo
Inglês
| MEDLINE | ID: mdl-38607410
7.
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
NPJ Breast Cancer
; 9(1): 81, 2023 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37803017
8.
The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Bioorg Med Chem Lett
; 22(11): 3732-8, 2012 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22542012
9.
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Bioorg Med Chem Lett
; 22(8): 2693-7, 2012 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22450127
10.
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Clin Cancer Res
; 28(7): 1383-1390, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35091441
11.
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.
Target Oncol
; 16(6): 761-771, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34687398
12.
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Clin Cancer Res
; 27(10): 2742-2754, 2021 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33602684
13.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Leuk Res
; 88: 106283, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31790983
14.
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Leukemia
; 33(2): 379-389, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30555165
15.
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(5): 1505, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38297094
16.
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Clin Cancer Res
; 13(12): 3713-23, 2007 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17575237
17.
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Clin Cancer Res
; 24(10): 2294-2303, 2018 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29463550
18.
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Mol Cancer Ther
; 5(5): 1280-9, 2006 May.
Artigo
Inglês
| MEDLINE | ID: mdl-16731761
19.
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Mol Cancer Ther
; 5(7): 1774-82, 2006 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-16891463
20.
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL.
Blood Adv
; 6(11): 3255-3259, 2022 06 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34991158